Form 4: Treace Medical Concepts Executive Exercises Stock Options
SEC Form 4 Filing
Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts, Inc., exercised stock options and acquired common stock on September 12, 2024.
Summary
- On September 12, 2024, Sean F. Scanlan, the Chief Innovation Officer of Treace Medical Concepts, Inc., exercised stock options.
- This transaction involved the acquisition of 33,750 shares of common stock at a price of $0.0972 per share.
- Following the transaction, Scanlan directly owns 250,074 shares of common stock, which includes 215,185 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's a standard practice for publicly traded companies to report such transactions to the SEC.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 12/15/2018 | Last installment vesting date for the stock option. |
| 09/12/2024 | Date of the stock option exercise and common stock acquisition. |
| 09/16/2024 | Date of the Form 4 filing. |
| 12/15/2024 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.